Pulmonary fibrosis

Contract Research Solutions (Pulmonary fibrosis model)

Image is for illustration purposes.Image is for illustration purposes.

Idiopathic pulmonary fibrosis (IPF) is chronic interstitial pneumonia of unknown causes. IPF is characterized by alveolar injury and interstitial inflammation followed by excessive deposition of extracellular matrix and destruction of lung architecture. The mortality rate of IPF is quite high (nearly 70% mortality at 5 years after diagnosis), while the current pharmacological interventions are largely limited.

Bleomycin (BLM)-induced pulmonary fibrosis is the most established disease model for IPF and widely used to investigate the efficacy and/or mechanism of therapeutic candidates.

SMC Laboratories has re-validated BLM-induced pulmonary fibrosis as a murine model translating non-clinical program into clinical practice.

Features and advantages of SMC Laboratories’ BLM-induced pulmonary fibrosis model

Uniform and reproducible phenotype
Efficient introduction of BLM by MicroSprayer®
CT evaluation of fibrotic lesions
In-life assessment as in clinical studies
Sampling scheme that allows all analyses in a single mouse
Maximum information (histology, biochemistry, RT-PCR etc.) with minimum animal number
Expert histology
Accumulated knowledge and experience across fibrosis models
Availability of positive control
Nintedanib (BIBF 1120)
Dexamethasone
Image is for illustration purposes.Image is for illustration purposes.

Study design

SMC Laboratories’ contract research will assist you with protocol design to generate reliable results from each study. All tests will be carried out at our own state-of-the-art facility located in Tokyo, Japan.

Sample design to assess the drug efficacy on pulmonary fibrosis:

Route of drug administration
po, iv, ip, sc, etc.
Treatment period
2-3 weeks [from day 0 (preventive)/day 7 (therapeutic) to day 20]
Baseline
STAM™ mouse at week 6 showing evidence of NASH (increase NAFLD activity score and serum transaminase), similar inclusion criteria to NASH patients.
Endpoints
Ashcroft score (MT staining), Collagen content (Sircol collagen assay /hydroxyproline assay).
Image is for illustration purposes.Image is for illustration purposes.

Assays

Histopathology

  • Ashcroft score (MT staining)
  • Immunohistochemical analyses for fibrotic markers

Biochemistry

  • Lung collagen content (Sircol collagen assay/hydroxyproline assay)

BALF analysis

  • Cytological analysis
  • Cytokine ELISA

Gene expression (Quantitative PCR)

Micro-CT analysis

  • Fibrosis distribution and density